相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Predictive Factors for Early HBeAg Seroconversion in Acute Exacerbation of Patients With HBeAg-Positive Chronic Hepatitis B
Hyoung Su Kim et al.
GASTROENTEROLOGY (2009)
Early Serum HBsAg Drop: A Strong Predictor of Sustained Virological Response to Pegylated Interferon Alfa-2a in HBeAg-Negative Patients
Rami Moucari et al.
HEPATOLOGY (2009)
Hepatitis B Virus Surface Antigen Levels: A Guide to Sustained Response to peginterferon alfa-2a in HBeAg-Negative Chronic Hepatitis B
Maurizia Rossana Brunetto et al.
HEPATOLOGY (2009)
Benefits and Risks of Interferon Therapy for Hepatitis B
Robert Perrillo
HEPATOLOGY (2009)
EASL Clinical Practice Guidelines: Management of chronic hepatitis B
Patrick Marcellin et al.
JOURNAL OF HEPATOLOGY (2009)
Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: A meta-analysis
Yong-Feng Yang et al.
ANTIVIRAL RESEARCH (2008)
Early hepatitis B virus DNA suppression can predict virologic response to peginterferon and lamivudine treatment
Henry Lik-Yuen Chan et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2008)
HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B
Michael W. Fried et al.
HEPATOLOGY (2008)
Drug therapy - Hepatitis B virus infection
Jules L. Dienstag
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Navigating the maze of hepatitis B treatments
Anna Suk-Fong Lok
GASTROENTEROLOGY (2007)
Hepatitis B virus genotype B is associated with better response to thymosin α1 therapy than genotype C
R-N. Chien et al.
JOURNAL OF VIRAL HEPATITIS (2006)
Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: A randomized controlled study
Jing You et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2006)
Predicting cirrhosis risk based on the level of circulating hepatitis B viral load
UH Iloeje et al.
GASTROENTEROLOGY (2006)
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level
CJ Chen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
GKK Lau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial
S Iino et al.
JOURNAL OF VIRAL HEPATITIS (2005)
Hepatitis B virus genotypes in korea: An endemic area of hepatitis B virus infection
BC Song et al.
INTERVIROLOGY (2005)
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised
HLA Janssen et al.
LANCET (2005)
Thymalfasin: an immune system enhancer for the treatment of liver disease
MH Sjogren
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2004)
Thymalfasin: an immune system enhancer for the treatment of liver disease
MH Sjogren
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2004)
Long-term outcomes of thymosin-α1 and interferon α-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B
M Saruc et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2003)
Peginterferon α-2a (40 kDa):: an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B
WGE Cooksley et al.
JOURNAL OF VIRAL HEPATITIS (2003)
Hepatitis B e antigen and the risk of hepatocellular carcinoma
HI Yang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials
D Moher et al.
LANCET (2001)
A randomized, controlled study of thymosin-α1 therapy in patients with anti-HBe, HBV-DNA-positive chronic hepatitis B
C Zavaglia et al.
DIGESTIVE DISEASES AND SCIENCES (2000)
分享论文
